Media releases
- February
- January
- 30-Jan-2012 Novartis extends commitment to help achieve final elimination of leprosy »
- 25-Jan-2012 Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 »
- 20-Jan-2012 CHMP recommends EU approval to update Novartis drug Glivec® label to include three year treatment for GIST patients after surgery »
- 20-Jan-2012 Novartis drug Signifor® recommended by CHMP for EU approval to treat patients with Cushing's disease »
- 19-Jan-2012 Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment »
- 18-Jan-2012 Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies that support public health goals »
- 13-Jan-2012 Novartis to restructure US business to strengthen competitive position in light of loss of Diovan® patent and announces charge for Rasilez®/Tekturna® »
- 08-Jan-2012 Novartis Consumer Health Inc. voluntarily recalls certain over-the-counter products in the US while Novartis Group strengthens quality standards across all manufacturing sites »
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
